Avastin bevacizumab: Phase III delayed

In 1Q08, DNA will begin the Phase III CALGB C40503 trial in 500 patients to evaluate an aromatase inhibitor or tamoxifen plus either Avastin 15 mg/kg or placebo. The company had planned to start the ...